Clinical Trial Update: SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of SNDX-5613 and gilteritinib for relapsed or refractory FLT3-mutated acute myeloid leukemia, including patients with K…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gilteritinib (gilteritinib)
• SNDX-5613

Snippet

Sponsor: Uma Borate | Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement | Phase 1 | Status: RECRUITING